Novo Nordisk A/S Q2 Earnings Call Highlights
Novo Nordisk reported Q2 adjusted sales of DKK 78.5 billion, with obesity care sales up 16% and GLP-1 diabetes up 2%. Adjusted gross margin fell to 78.2% from 82.7% due to lower prices, about DKK 3 billion one-time manufacturing-cost items, and FX. The company raised 2026 outlook to 0% to -6% adjusted sales and operating profit growth. ZEUS ziltivekimab trial missed its primary endpoint (HR 0.99).
How this was made
The 30-second read
Why it matters
For trading, the key tension is a guidance raise versus deteriorating gross margin and a cardiovascular outcomes trial failure, alongside explicit assumptions about U.S. competition, Medicaid coverage changes, and most-favored-nation effects.
Market read
Traders can update positioning based on raised 2026 expectations, quantified margin headwinds, and a concrete pipeline setback that may affect risk premium for cardiometabolic outcomes assets.
What to watch
The raised 2026 outlook assumes U.S. sales decline and intensifying competition; traders should weigh whether margin recovery depends on realized price stabilization versus one-time manufacturing and currency effects.
Background
The piece summarizes Novo Nordisk’s Q2 earnings call, focusing on obesity GLP-1 access dynamics, margin drivers, 2026 guidance, and pipeline trial updates.
Ticker impact
Novo Nordisk raised 2026 outlook despite Q2 gross margin falling to 78.2% and disclosed ZEUS ziltivekimab failing to meet its primary CV endpoint.
Choppy trading risk, with upside bias from raised 2026 expectations but downside pressure from ZEUS failure and margin headwinds.
The article provides multiple decision-relevant updates: raised 2026 outlook, quantified margin drivers, U.S. self-pay mix shift, and a primary endpoint miss (HR 0.99) plus more frequent serious infections in ZEUS.
Market effects
Reinforces competitive and pricing pressure dynamics in U.S. obesity GLP-1 markets while highlighting continued international volume growth.
U.S. channel mix shift toward self-pay and reduced Medicaid coverage expectations are key for domestic sentiment; international launches (UK, UAE) support ex-U.S. demand.
ZEUS outcome and CagriSema regulatory timing influence broader GLP-1 and cardiometabolic pipeline risk appetite globally.
Counterpoint
The ZEUS miss may be less damaging if investors focus on ongoing ARTEMIS and HERMES readouts and on CagriSema’s obesity program progress.
Key entities
- companyNovo Nordisk A/S
Raised 2026 outlook, reported Q2 margin decline, and disclosed ZEUS ziltivekimab primary endpoint failure.
- clinical_programziltivekimab (ZEUS trial)
Did not meet primary objective; hazard ratio for major adverse cardiovascular events was 0.99, with serious infections more frequent than placebo.
- clinical_programCagriSema (REDEFINE 9)
REDEFINE 9 completed, showing superior weight loss vs placebo; U.S. regulatory decision expected near end of 2026 with potential 2027 launch.
